DOSIMETRIA CLÍNICA

PUBLICAÇÕES EM DOSIMETRIA

​

PubMed Results (04/2023)

1.

Accuracy in dosimetry of diagnostic agents: impact of the number of source tissues used in whole organ S value-based calculations.

Josefsson A, Siritantikorn K, Ranka S, de Amorim de Carvalho JW, Buchpiguel CA, Sapienza MT, Bolch WE, Sgouros G.

EJNMMI Res. 2020 Mar 19;10(1):26. doi: 10.1186/s13550-020-0614-6.

PMID: 32189087 Free PMC article.

2.

Radionuclide therapy: current status and prospects for internal dosimetry in individualized therapeutic planning.

Sapienza MT, Willegaignon J.

Clinics (Sao Paulo). 2019;74:e835. doi: 10.6061/clinics/2019/e835. Epub 2019 Jul 29.

PMID: 31365617 Free PMC article. Review.

3.

Pediatric 131I-MIBG Therapy for Neuroblastoma: Whole-Body 131I-MIBG Clearance, Radiation Doses to Patients, Family Caregivers, Medical Staff, and Radiation Safety Measures.

Willegaignon J, Crema KP, Oliveira NC, Pelissoni RA, Coura-Filho GB, Sapienza MT, Buchpiguel CA.

Clin Nucl Med. 2018 Aug;43(8):572-578. doi: 10.1097/RLU.0000000000002158.

PMID: 29916922

4.

Comparative Dosimetry for 68Ga-DOTATATE: Impact of Using Updated ICRP Phantoms, S Values, and Tissue-Weighting Factors.

Josefsson A, Hobbs RF, Ranka S, Schwarz BC, Plyku D, Willegaignon de Amorim de Carvalho J, Buchpiguel CA, Sapienza MT, Bolch WE, Sgouros G.

J Nucl Med. 2018 Aug;59(8):1281-1288. doi: 10.2967/jnumed.117.203893. Epub 2018 Feb 9.

PMID: 29439017 Free PMC article.

5.

Estimating (131)I biokinetics and radiation doses to the red marrow and whole body in thyroid cancer patients: probe detection versus image quantification.

Willegaignon J, Pelissoni RA, Lima BC, Sapienza MT, Coura-Filho GB, Queiroz MA, Buchpiguel CA.

Radiol Bras. 2016 May-Jun;49(3):150-7. doi: 10.1590/0100-3984.2015.0079.

PMID: 27403014 Free PMC article.

6.

Prediction of iodine-131 biokinetics and radiation doses from therapy on the basis of tracer studies: an important question for therapy planning in nuclear medicine.

Willegaignon J, Pelissoni RA, Lima BC, Sapienza MT, Coura-Filho GB, Buchpiguel CA.

Nucl Med Commun. 2016 May;37(5):473-9. doi: 10.1097/MNM.0000000000000465.

PMID: 26671852

7.

Diagnostic reference level: an important tool for reducing radiation doses in adult and pediatric nuclear medicine procedures in Brazil.

Willegaignon J, Braga LF, Sapienza MT, Coura-Filho GB, Cardona MA, Alves CE, Gutterres RF, Buchpiguel CA.

Nucl Med Commun. 2016 May;37(5):525-33. doi: 10.1097/MNM.0000000000000462.

PMID: 26657219

8.

Clinical and Dosimetric Variables Related to Outcome After Treatment of Graves' Disease With 550 and 1110 MBq of 131I: Results of a Prospective Randomized Trial.

Sapienza MT, Coura-Filho GB, Willegaignon J, Watanabe T, Duarte PS, Buchpiguel CA.

Clin Nucl Med. 2015 Sep;40(9):715-9. doi: 10.1097/RLU.0000000000000840.

PMID: 26204202 Clinical Trial.

9.

Graves' disease radioiodine-therapy: choosing target absorbed doses for therapy planning.

Willegaignon J, Sapienza MT, Coura-Filho GB, Watanabe T, Traino AC, Buchpiguel CA.

Med Phys. 2014 Jan;41(1):012503. doi: 10.1118/1.4846056.

PMID: 24387527

10.

Radioiodine therapy for Graves disease: thyroid absorbed dose of 300 Gy-tuning the target for therapy planning.

Willegaignon J, Sapienza MT, Buchpiguel CA.

Clin Nucl Med. 2013 Apr;38(4):231-6. doi: 10.1097/RLU.0b013e3182816717.

PMID: 23429386 Clinical Trial.

11.

Comparison of different dosimetric methods for red marrow absorbed dose calculation in thyroid cancer therapy.

Willegaignon J, Sapienza MT, Buchpiguel CA.

Radiat Prot Dosimetry. 2012 Apr;149(2):138-46. doi: 10.1093/rpd/ncr214. Epub 2011 May 17.

PMID: 21586539

12.

[Radioiodine therapy of differentiated thyroid cancer: radiologic impact of out-patient treatment with 100 to 150 mCi Iodine-131 activities].

Sapienza MT, Willegaignon J, Ono CR, Watanabe T, Guimarães MI, Gutterres RF, Maréchal MH, Buchpiguel CA.

Arq Bras Endocrinol Metabol. 2009 Apr;53(3):318-25. doi: 10.1590/s0004-27302009000300004.

PMID: 19578592 Portuguese.

13.

Correction factors for more accurate estimates of exposure rates near radioactive patients: experimental, point, and line source models.

Willegaignon J, Guimarães MI, Stabin MG, Sapienza MT, Malvestiti LF, Marone MM, Sordi GM.

Health Phys. 2007 Dec;93(6):678-88. doi: 10.1097/01.HP.0000275298.69543.5c.

PMID: 17993848

14.

A new proposal for monitoring patients in nuclear medicine.

Willegaignon J, Guimarães MI, Sapienza MT, Stabin MG, Malvestiti LF, Marone M, Sordi GM.

Health Phys. 2006 Dec;91(6):624-9. doi: 10.1097/01.HP.0000225467.10064.34.

PMID: 17099406

15.

Evaluation of the potential absorbed doses from patients based on whole-body 131I clearance in thyroid cancer therapy.

Willegaignon J, Stabin MG, Guimarães MI, Malvestiti LF, Sapienza MT, Maroni M, Sordi GM.

Health Phys. 2006 Aug;91(2):123-7. doi: 10.1097/01.HP.0000206041.25242.c0.

PMID: 16832193 Clinical Trial.

16.

131I effective half-life (Teff) for patients with thyroid cancer.

Willegaignon J, Malvestiti LF, Guimarães MI, Sapienza MT, Endo IS, Neto GC, Marone M, Sordi GM.

Health Phys. 2006 Aug;91(2):119-22. doi: 10.1097/01.HP.0000202232.98823.87.

PMID: 16832192

17.

[Radioiodine therapy for differentiated thyroid carcinoma: methods used to increase the radiation absorbed dose].

Sapienza MT, Endo IS, Campos Neto GC, Tavares MG, Marone MM.

Arq Bras Endocrinol Metabol. 2005 Jun;49(3):341-9. doi: 10.1590/s0004-27302005000300004. Epub 2006 Mar 16.

PMID: 16543987 Review. Portuguese.

18.

Retrospective evaluation of bone pain palliation after samarium-153-EDTMP therapy.

Sapienza MT, Ono CR, Guimarães MI, Watanabe T, Costa PA, Buchpiguel CA.

Rev Hosp Clin Fac Med Sao Paulo. 2004 Dec;59(6):321-8. doi: 10.1590/s0041-87812004000600003. Epub 2005 Jan 11.

PMID: 15654484

19.

Radiation safety measures in diagnostic nuclear medicine, based on the potential radiation dose emitted by radioactive patients.

Willegaignon J, Fernandes SCP, Pelissoni RA, Coura-Filho GB, Sapienza MT, Buchpiguel CA.

Radiol Bras. 2023 Jan-Feb;56(1):13-20. doi: 10.1590/0100-3984.2022.0064.

PMID: 36926359 Free PMC article.

20.

Ultrasonography Echotexture as a surrogate for Sialadenitis secondary to 131I Radioiodine Therapy for differentiated Thyroid Cancer: a review and metaanalysis.

Lima GAS, López RVM, Ozório GA, de Freitas RMC, Willegaignon J, Sapienza MT, Chammas MC, Coura-Filho GB.

Clinics (Sao Paulo). 2020 Oct 19;75:e1843. doi: 10.6061/clinics/2020/e1843. eCollection 2020.

PMID: 33084769 Free PMC article.

21.

Evaluation of Parotid Salivary Gland Echo Texture by Ultrasound Examinations and Correlation With Whole-Body Scintigraphy After Radioiodine Therapy in Patients With Differentiated Thyroid Carcinoma.

Simões Lima GA, López RVM, de Freitas RMC, Willegaignon J, Sapienza MT, Chammas MC, Coura-Filho GB.

J Ultrasound Med. 2020 Sep;39(9):1811-1818. doi: 10.1002/jum.15289. Epub 2020 Apr 20.

PMID: 32309884

22.

Effects of Thyroid Hormone Withdrawal and Recombinant Human Thyrotropin on Glomerular Filtration Rate During Radioiodine Therapy for Well-Differentiated Thyroid Cancer.

Coura-Filho GB, Willegaignon J, Buchpiguel CA, Sapienza MT.

Thyroid. 2015 Dec;25(12):1291-6. doi: 10.1089/thy.2015.0173. Epub 2015 Nov 5.

PMID: 26446582 Clinical Trial.

23.

Dose Calibrator Linearity Testing: Radioisotope (99m)Tc or (18)F? An Alternative for Reducing Costs in Nuclear Medicine Quality Control.

Willegaignon J, Sapienza MT, Coura-Filho GB, Garcez AT, Alves CE, Cardona MR, Gutterres RF, Buchpiguel CA.

World J Nucl Med. 2015 Sep-Dec;14(3):165-70. doi: 10.4103/1450-1147.163245.

PMID: 26420986 Free PMC article.

24.

Dose calibrator linearity test: (99m)Tc versus (18)F radioisotopes.

Willegaignon J, Sapienza MT, Coura-Filho GB, Garcez AT, Alves CE, Cardona MA, Gutterres RF, Buchpiguel CA.

Radiol Bras. 2015 Jan-Feb;48(1):26-32. doi: 10.1590/0100-3984.2014.0018.

PMID: 25798005 Free PMC article.

25.

Determining thyroid (131)I effective half-life for the treatment planning of Graves' disease.

Willegaignon J, Sapienza MT, Coura Filho GB, Traino AC, Buchpiguel CA.

Med Phys. 2013 Feb;40(2):022502. doi: 10.1118/1.4788660.

PMID: 23387769

26.

[Correlation between thyroid volume determined either by ultrasound or by scintigraphy and its implications in dosimetric radioiodine calculations in Graves disease treatment].

Vieira Lde O, Kubo R, Sapienza MT, Willegaignon J, Chammas MC, Coura-Filho GB, Ono CR, Watanabe T, Sado HN, Buchpiguel CA.

Arq Bras Endocrinol Metabol. 2011 Dec;55(9):696-700. doi: 10.1590/s0004-27302011000900005.

PMID: 22231972 Portuguese.

27.

Outpatient radioiodine therapy for thyroid cancer: a safe nuclear medicine procedure.

Willegaignon J, Sapienza M, Ono C, Watanabe T, Guimarães MI, Gutterres R, Marechal MH, Buchpiguel C.

Clin Nucl Med. 2011 Jun;36(6):440-5. doi: 10.1097/RLU.0b013e3182184fa0.

PMID: 21552020 Clinical Trial.

28.

Is it necessary to reduce the radioiodine dose in patients with thyroid cancer and renal failure?

Willegaignon J, Ribeiro VP, Sapienza M, Ono C, Watanabe T, Buchpiguel C.

Arq Bras Endocrinol Metabol. 2010 Jun;54(4):413-8. doi: 10.1590/s0004-27302010000400011.

PMID: 20625654

29.

Could the treatment of differentiated thyroid carcinoma with 3.7 and 5.55 GBq of (131I)NaI, on an outpatient basis, be safe?

de Carvalho JW, Sapienza M, Ono C, Watanabe T, Guimarães MI, Gutterres R, Marechal MH, Buchpiguel C.

Nucl Med Commun. 2009 Jul;30(7):533-41. doi: 10.1097/MNM.0b013e32832b79bc.

PMID: 19436231 Clinical Trial.